Logo

AstraZeneca Presents Results of Farxiga (dapagliflozin) in P-lll DAPA-CKD Study for Chronic Kidney Disease at ASN Kidney Week 2020

Share this

AstraZeneca Presents Results of Farxiga (dapagliflozin) in P-lll DAPA-CKD Study for Chronic Kidney Disease at ASN Kidney Week 2020

Shots:

  • The P-lll DAPA-CKD study involves the assessing of Farxiga (qd- 10 mg) + SOC vs PBO in 4304 patients with CKD stages 2-4 and elevated urinary albumin excretion- with/ out T2D
  • Results of subgroup analysis : RRR & ARR (5.8% & 37%) for patients whose CKD was primarily driven by diabetic kidney disease; (25% & 2.2%) for high B.P.; (57% & 7.5%) for glomerulonephritis; (42% & 5.0%) for CKD of other or unknown causes (ARR = 5.0%) respectively. Also showed reduction in in all-cause mortality as secondary outcome
  • Farxiga (PO- qd) is a first-in-class SGLT2 inhibitor indicated in adults for the treatment of insufficiently controlled T2D as both monotherapy & combination regimen as an adjunct to diet and exercise to improve glycemic control and has received FDA’s BTD & CHMP’s recommendation in Oct’2020

 ­ Ref: AstraZeneca | Image: NPR

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions